Navigation Links
A Once-Daily Oral Drug for Chronic Obstructive Pulmonary Disease That Treats COPD-Related Inflammation Could Achieve Blockbuster Status
Date:2/27/2008

Although Physicians Report Satisfaction with GlaxoSmithKline's Advair and Boehringer Ingelheim/Pfizer's Spiriva, Significant Need Remains for a Novel Anti-Inflammatory Drug, According to a New Report from Decision Resources

WALTHAM, Mass., Feb. 27 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that surveyed physicians indicate that a novel, non- steroidal, anti-inflammatory agent for COPD that improves lung function could capture a significant share of the COPD market by replacing GlaxoSmithKline's Advair (also marketed as Seretide and Adoair).

The new report entitled Chronic Obstructive Pulmonary Disease: Opportunity Lies in Drugs That Address COPD-Related Inflammation finds that an oral, once- daily drug that treats COPD-related inflammation and improves lung function could achieve blockbuster status by 2016. Although an effective anti- inflammatory drug for COPD could replace Advair, it would likely be used in combination with Boehringer Ingelheim/Pfizer's Spiriva, according to the report. Spiriva's efficacy, safety, and convenience make it the current gold standard treatment for COPD but Advair's higher price, longer presence on the market and high prescribing by doctors made Advair the COPD market-share leader in 2006.

The report also finds that, following its approval in 2011 for the indication, Forest Laboratories/Almirall Prodesfarma's aclidinium will become the clinical gold standard for COPD by 2016. Aclidinium, a long-acting muscarinic antagonist (LAMA), will achieve gold standard status by 2016 because of its faster onset of action when compared to Spiriva.

"Because Spiriva is the first-to-market LAMA and has extensive clinical data and physician experience, we don't expect aclidinium to immediately achieve wide acceptance upon launch as the gold standard for COPD as physicians must first gain clinical experience with the drug," said Regina Jammen, analyst at Decision Resources. "We expect that clinical trials, specifically the UPLIFT trial, will provide results showing the benefits of the long-term use of Spiriva in COPD patients, and these results are likely to be generalized to other agents in the LAMA drug class, such as aclidinium."

About the Report

Chronic Obstructive Pulmonary Disease: Opportunity Lies in Drugs That Address COPD-Related Inflammation is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price- per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Labopharms Once-Daily Tramadol Approved in South Korea and Australia
2. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
3. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
4. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
5. ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily)
6. Once-Daily Exjade(R) Shown to Remove Toxic Iron From the Heart and Liver, According to Data Presented at ASH
7. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
8. Labopharm appeals FDAs decision on once-daily tramadol
9. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
10. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
11. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's ... President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. ... 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the role ...
(Date:10/13/2017)... ... , ... PurhealthRX , a leading Health and Nutrition Company, is announcing ... full spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the ... incorporated into liquid products, while reducing costs to end users. , The team of ...
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & Associates ... special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to date ... elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded by ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers care ... have a waiver for care if the client has a cognitive impairment diagnosis. ... for care, is often waived, so the benefits from their insurance start immediately,” said ...
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... COPENHAGEN, Denmark , Oct. 2, 2017 The ... tool in the struggle to reverse the tide of prescription ... plan for regulating their medicine intake and stepping down their ... is set to launch in December 2017; the first 100,000 ... access. Learn more at http://www.rebound-solution.com/ ...
(Date:9/27/2017)... Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... its MyDario product is expected to appear on The Dr. Oz Show ... Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked off ... The segment features ...
(Date:9/22/2017)... , Sept. 22, 2017  As the latest ... Senators Bill Cassidy (R-LA) and Lindsey ... notes that the medical device industry is in an ... device tax, the 2.3% excise tax on medical device ... they also want covered patients, increased visits and hospital ...
Breaking Medicine Technology: